Dyne Capex To Revenue vs Days Payables Outstanding Analysis

DYN Stock

USD 31.88 0.68 2.18%

Dyne TherapeuticsInc financial indicator trend analysis is much more than just examining Dyne TherapeuticsInc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dyne TherapeuticsInc is a good investment. Please check the relationship between Dyne TherapeuticsInc Capex To Revenue and its Days Payables Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Dyne Stock, please use our How to Invest in Dyne TherapeuticsInc guide.

Capex To Revenue vs Days Payables Outstanding

Capex To Revenue vs Days Payables Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dyne TherapeuticsInc Capex To Revenue account and Days Payables Outstanding. At this time, the significance of the direction appears to have very week relationship.

The correlation between Dyne TherapeuticsInc's Capex To Revenue and Days Payables Outstanding is 0.23. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Days Payables Outstanding in the same time period over historical financial statements of Dyne TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of Dyne TherapeuticsInc's Capex To Revenue and Days Payables Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Dyne TherapeuticsInc are associated (or correlated) with its Days Payables Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Days Payables Outstanding has no effect on the direction of Capex To Revenue i.e., Dyne TherapeuticsInc's Capex To Revenue and Days Payables Outstanding go up and down completely randomly.

Correlation Coefficient

0.23

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Days Payables Outstanding

Most indicators from Dyne TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dyne TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Dyne Stock, please use our How to Invest in Dyne TherapeuticsInc guide.As of the 2nd of June 2024, Issuance Of Capital Stock is likely to grow to about 126.9 M, while Selling General Administrative is likely to drop about 22 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.1M	1.7M	1.7M	997.5K
Research Development	121.3M	142.8M	210.8M	221.3M

Reconciled Depreciation Research Development

Dyne TherapeuticsInc fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.8	0.96	0.96	0.88	0.93	0.2	0.78	0.9	0.65	1.0	0.44	0.67	-0.22	-0.34	0.69	0.49	0.33	0.82	-0.11	0.76	0.8	0.99	0.93	0.91	0.77
Short Long Term Debt Total	0.8		0.71	0.77	0.5	0.65	-0.03	0.99	0.78	0.72	0.78	0.54	0.72	-0.09	0.2	0.12	-0.1	0.23	1.0	0.2	0.34	0.54	0.86	0.65	0.84	0.83
Other Current Liab	0.96	0.71		0.97	0.87	0.95	0.23	0.7	0.92	0.52	0.97	0.33	0.53	-0.1	-0.44	0.75	0.59	0.25	0.72	-0.13	0.74	0.75	0.94	0.95	0.82	0.65
Total Current Liabilities	0.96	0.77	0.97		0.86	0.93	0.34	0.76	0.98	0.58	0.96	0.3	0.58	-0.1	-0.33	0.67	0.48	0.22	0.78	-0.1	0.74	0.72	0.94	0.93	0.88	0.74
Total Stockholder Equity	0.88	0.5	0.87	0.86		0.85	0.54	0.47	0.8	0.51	0.88	0.36	0.52	-0.34	-0.51	0.84	0.67	0.24	0.53	-0.38	0.95	0.75	0.79	0.85	0.8	0.46
Property Plant And Equipment Net	0.93	0.65	0.95	0.93	0.85		0.23	0.66	0.87	0.37	0.96	0.11	0.38	-0.16	-0.48	0.78	0.62	0.28	0.66	-0.08	0.79	0.78	0.91	1.0	0.74	0.71
Current Deferred Revenue	0.2	-0.03	0.23	0.34	0.54	0.23		-0.06	0.4	0.12	0.18	-0.05	0.1	-0.33	-0.12	0.36	0.21	-0.24	0.0	-0.53	0.62	0.22	0.08	0.23	0.28	-0.06
Net Debt	0.78	0.99	0.7	0.76	0.47	0.66	-0.06		0.77	0.63	0.77	0.45	0.63	-0.05	0.2	0.1	-0.1	0.21	0.99	0.26	0.32	0.51	0.85	0.66	0.78	0.82
Accounts Payable	0.9	0.78	0.92	0.98	0.8	0.87	0.4	0.77		0.59	0.89	0.27	0.59	-0.04	-0.23	0.57	0.37	0.16	0.79	-0.06	0.67	0.64	0.89	0.87	0.87	0.74
Cash	0.65	0.72	0.52	0.58	0.51	0.37	0.12	0.63	0.59		0.59	0.84	1.0	-0.28	0.14	0.18	-0.02	0.31	0.73	-0.19	0.34	0.51	0.67	0.37	0.88	0.6
Non Current Assets Total	1.0	0.78	0.97	0.96	0.88	0.96	0.18	0.77	0.89	0.59		0.39	0.6	-0.2	-0.38	0.71	0.53	0.32	0.79	-0.1	0.77	0.8	0.98	0.96	0.88	0.76
Non Currrent Assets Other	0.44	0.54	0.33	0.3	0.36	0.11	-0.05	0.45	0.27	0.84	0.39		0.82	-0.26	0.15	0.05	-0.07	0.2	0.54	-0.18	0.18	0.3	0.44	0.11	0.63	0.23
Cash And Short Term Investments	0.67	0.72	0.53	0.58	0.52	0.38	0.1	0.63	0.59	1.0	0.6	0.82		-0.27	0.11	0.2	0.01	0.39	0.73	-0.17	0.35	0.53	0.68	0.38	0.89	0.61
Net Receivables	-0.22	-0.09	-0.1	-0.1	-0.34	-0.16	-0.33	-0.05	-0.04	-0.28	-0.2	-0.26	-0.27		-0.01	-0.2	-0.01	0.07	-0.11	0.8	-0.43	-0.64	-0.16	-0.16	-0.26	-0.01
Good Will	-0.34	0.2	-0.44	-0.33	-0.51	-0.48	-0.12	0.2	-0.23	0.14	-0.38	0.15	0.11	-0.01		-0.83	-0.92	-0.24	0.19	0.28	-0.53	-0.24	-0.26	-0.48	-0.1	-0.04
Common Stock Total Equity	0.69	0.12	0.75	0.67	0.84	0.78	0.36	0.1	0.57	0.18	0.71	0.05	0.2	-0.2	-0.83		0.95	0.24	0.14	-0.4	0.85	0.64	0.6	0.78	0.48	0.29
Common Stock Shares Outstanding	0.49	-0.1	0.59	0.48	0.67	0.62	0.21	-0.1	0.37	-0.02	0.53	-0.07	0.01	-0.01	-0.92	0.95		0.24	-0.08	-0.28	0.69	0.41	0.41	0.62	0.26	0.14
Short Term Investments	0.33	0.23	0.25	0.22	0.24	0.28	-0.24	0.21	0.16	0.31	0.32	0.2	0.39	0.07	-0.24	0.24	0.24		0.23	0.21	0.16	0.23	0.34	0.28	0.36	0.35
Non Current Liabilities Total	0.82	1.0	0.72	0.78	0.53	0.66	0.0	0.99	0.79	0.73	0.79	0.54	0.73	-0.11	0.19	0.14	-0.08	0.23		0.17	0.37	0.56	0.87	0.66	0.85	0.83
Inventory	-0.11	0.2	-0.13	-0.1	-0.38	-0.08	-0.53	0.26	-0.06	-0.19	-0.1	-0.18	-0.17	0.8	0.28	-0.4	-0.28	0.21	0.17		-0.44	-0.5	-0.02	-0.08	-0.15	0.23
Other Current Assets	0.76	0.34	0.74	0.74	0.95	0.79	0.62	0.32	0.67	0.34	0.77	0.18	0.35	-0.43	-0.53	0.85	0.69	0.16	0.37	-0.44		0.69	0.66	0.79	0.65	0.41
Other Stockholder Equity	0.8	0.54	0.75	0.72	0.75	0.78	0.22	0.51	0.64	0.51	0.8	0.3	0.53	-0.64	-0.24	0.64	0.41	0.23	0.56	-0.5	0.69		0.77	0.78	0.71	0.5
Total Liab	0.99	0.86	0.94	0.94	0.79	0.91	0.08	0.85	0.89	0.67	0.98	0.44	0.68	-0.16	-0.26	0.6	0.41	0.34	0.87	-0.02	0.66	0.77		0.91	0.91	0.83
Property Plant And Equipment Gross	0.93	0.65	0.95	0.93	0.85	1.0	0.23	0.66	0.87	0.37	0.96	0.11	0.38	-0.16	-0.48	0.78	0.62	0.28	0.66	-0.08	0.79	0.78	0.91		0.74	0.71
Total Current Assets	0.91	0.84	0.82	0.88	0.8	0.74	0.28	0.78	0.87	0.88	0.88	0.63	0.89	-0.26	-0.1	0.48	0.26	0.36	0.85	-0.15	0.65	0.71	0.91	0.74		0.76
Short Term Debt	0.77	0.83	0.65	0.74	0.46	0.71	-0.06	0.82	0.74	0.6	0.76	0.23	0.61	-0.01	-0.04	0.29	0.14	0.35	0.83	0.23	0.41	0.5	0.83	0.71	0.76

Click cells to compare fundamentals

Dyne TherapeuticsInc Account Relationship Matchups

Dyne TherapeuticsInc fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	16.4M	353.3M	425.7M	306.3M	165.1M	156.8M
Short Long Term Debt Total	8.4B	3.4M	32.6M	30.5M	27.4M	26.0M
Other Current Liab	1.1M	7.5M	20.8M	18.2M	23.4M	22.3M
Total Current Liabilities	2.4M	11.0M	28.7M	28.1M	51.1M	48.5M
Total Stockholder Equity	14.0M	342.4M	368.2M	252.4M	91.3M	86.7M
Property Plant And Equipment Net	1.5M	1.9M	41.0M	38.4M	33.4M	31.7M
Net Debt	(14.6M)	(300.9M)	(168.2M)	(141.7M)	(94.2M)	(89.5M)
Accounts Payable	1.3M	3.4M	4.0M	5.3M	22.9M	21.8M
Cash	14.6M	300.9M	200.8M	172.1M	121.6M	115.5M
Non Current Assets Total	1.7M	8.0M	43.3M	50.3M	35.7M	33.9M
Non Currrent Assets Other	191K	3.8M	2.3M	9.6M	(1.0)	(0.95)
Cash And Short Term Investments	14.6M	345.3M	376.6M	256.0M	123.1M	116.9M
Common Stock Shares Outstanding	45.4M	14.4M	50.9M	52.0M	59.7M	56.7M
Liabilities And Stockholders Equity	16.4M	353.3M	425.7M	306.3M	165.1M	156.8M
Non Current Liabilities Total	42K	3.4M	28.7M	25.9M	22.7M	21.6M
Other Current Assets	127K	3.8M	5.8M	9.6M	6.3M	6.0M
Other Stockholder Equity	6.4M	421.6M	596.9M	649.5M	723.8M	687.6M
Total Liab	2.4M	11.0M	57.5M	54.0M	73.8M	70.1M
Property Plant And Equipment Gross	1.5M	1.9M	42.9M	42.0M	38.7M	36.7M
Total Current Assets	14.8M	345.3M	382.4M	256.0M	129.4M	122.9M
Accumulated Other Comprehensive Income	0.0	(27K)	(269K)	(571K)	(656.7K)	(689.5K)
Retained Earnings	(19.7M)	(79.2M)	(228.5M)	(396.6M)	(632.5M)	(664.1M)
Net Tangible Assets	(13.4M)	342.4M	368.2M	252.4M	290.2M	207.8M
Net Invested Capital	(13.4M)	342.4M	368.2M	252.4M	91.3M	86.7M
Net Working Capital	12.4M	338.1M	353.7M	237.5M	78.3M	74.4M
Property Plant Equipment	1.5M	1.9M	41.0M	38.4M	44.2M	46.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Dyne TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeuticsinc Stock:

How To Invest In Dyne

Details

Is Dyne Stock a good investment?

Details

What is Dyne TherapeuticsInc's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Dyne Stock, please use our How to Invest in Dyne TherapeuticsInc guide.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Dyne Stock analysis

When running Dyne TherapeuticsInc's price analysis, check to measure Dyne TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dyne TherapeuticsInc is operating at the current time. Most of Dyne TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Dyne TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dyne TherapeuticsInc's price. Additionally, you may evaluate how the addition of Dyne TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.

	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Global Correlations Find global opportunities by holding instruments from different markets
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments

Is Dyne TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne TherapeuticsInc. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.98)

Return On Assets

(0.41)

Return On Equity

(0.71)

The market value of Dyne TherapeuticsInc is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Dyne TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne TherapeuticsInc's market value can be influenced by many factors that don't directly affect Dyne TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dyne TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dyne Capex To Revenue vs Days Payables Outstanding Analysis

Capex To Revenue vs Days Payables Outstanding

Capex To Revenue vs Days Payables Outstanding Correlation Analysis

Correlation Coefficient

Capex To Revenue

Days Payables Outstanding

Dyne TherapeuticsInc fundamental ratios Correlations

Dyne TherapeuticsInc Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dyne TherapeuticsInc fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Dyne Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.92	Good Will
Common Stock Total Equity	- 0.83	Good Will
Other Stockholder Equity	- 0.64	Net Receivables
Other Current Assets	- 0.53	Good Will
Inventory	- 0.53	Current Deferred Revenue
Good Will	- 0.51	Total Stockholder Equity